Document is current
Any future updates will be listed below
-
Authors
Coma, Ermengol https://orcid.org/0000-0001-8000-3321
Martínez-Marcos, Montserrat https://orcid.org/0009-0007-3390-8372
Hermosilla, Eduardo https://orcid.org/0000-0002-3031-0304
Mendioroz, Jacobo https://orcid.org/0000-0002-8883-2180
Reñé, Anna
Fina, Francesc https://orcid.org/0000-0001-7106-5635
Perramon-Malavez, Aida https://orcid.org/0000-0002-6057-5127
Prats, Clara https://orcid.org/0000-0002-1398-7559
Antón, Andrés https://orcid.org/0000-0002-1476-0815
Soriano-Arandes, Antoni https://orcid.org/0000-0001-9613-7228
Cabezas, Carmen https://orcid.org/0000-0002-4291-0454
- License Information
-
More Information
Article History
Received: 15 May 2025
Revised: 24 July 2025
Accepted: 24 August 2025
First Online: 13 September 2025
Declarations
:
: The study was conducted in accordance with national and international regulations (Declaration of Helsinki, last update Fortaleza, Brazil 2013) regarding ethical aspects. Furthermore, it was carried out in strict compliance with the ethical principles of biomedical research and the current legislation in Spain. Finally, this study was approved by the Clinical Research Ethics Committee of IDIAP Jordi Gol (reference number 24/015-EOm).
: Not applicable, as the study received a waiver of informed consent from the ethics committee.
: All the authors approved the manuscript for publication.
: AS-A have received funding from Sanofi, MSD and Pfizer for lectures and for attending international meetings and congresses. The other authors declare no competing interests.
